Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2019

View Archived Issues

RUNX1 mRNA-containing nanomicelles prevent intervertebral disk degeneration in mice

BioCryst advancing factor D inhibitor BCX-9930 into clinic for complement-mediated diseases

Optogenetics helps understand TDP-43 aggregates

Tackling tendonitis

PIGU overexpression aids in the prognosis stratification of patients with HCC

CROI 2019: With additional long-term remission, number of possible HIV cures doubles to 2

Preliminary phase II data presented for RX-3117 in advanced urothelial cancer

RCN1 as a novel biomarker of prognosis in non-small cell lung cancer

PCDHGA7 downregulation in KRAS wild-type colorectal cancer is correlated with poor clinical outcomes

Ascendis Pharma presents results from phase III heiGHt trial for TransCon hGH

Nanoparticle MRI contrast agent SN-132D shows preclinical efficacy and safety

MyoKardia announces safety and efficacy data from PIONEER-OLE study of mavacamten

PsiOxus initiates first-in-human study of NG-350A

CARB-X funding to support Contrafect's development of amurins to treat Gram-negative pathogens

Principia Biopharma reports phase I data for PRN-2246

FORMA Therapeutics synthesizes new USP28 and USP25 inhibitors

University of Arizona discloses compounds for Parkinson's disease

Denali Therapeutics identifies EIF2B activators

Guangzhou Henovcom Bioscience describes ENPP2 inhibitors

Harvard College patent describes lincosamide antibiotics

BioXcel collaborates with Merck KGaA and Pfizer to study avelumab with BXCL-701 and NKTR-214

Akeso enrolling in phase Ib/II study of AK-104 for advanced solid tumors and gastric cancer

Grant funds IVI to provide support for typhoid conjugate vaccine studies

New phase Ib trial explores use of AVID-200 in diffuse cutaneous systemic sclerosis

FDA clears IND for phase I study of KO-539 in relapsed or refractory AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...